Stay updated with breaking news from Paul Macleman. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Clinical-stage drug discovery company AdAlta Ltd (ASX:1AD) has raised $1.65 million in an oversubscribed placement to institutional and sophisticated...
Tim Boreham outlines the rise and fall of IDT Australia, and its potential revival in the cannabis and psychedelic drug market
AdAlta Ltd (ASX:1AD) is well on the way to an early return to the clinic with the novel therapeutic products from its i-body platform after raising $1.28...
AdAlta Ltd (ASX:1AD) is seeking an early return to clinical trials of its lead asset, AD-214, with a $3.5 million non-renounceable rights offer. The...
Tim Boreham digs deep into the evolving world of cancer diagnostics, highlighting the newly named Inoviq Ltd